Clinical Trials Browser

NCT01306045 2024-10-01

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

Phase 2 Completed

647 enrolled 17 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Thymoma, Small Cell Lung Carcinoma

NCT01622868 2023-10-17

Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer

Phase 2 Completed

143 enrolled 24 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT00684983 2020-03-24

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer

Phase 2 Completed

64 enrolled 13 charts

Breast

Insulin-Like Growth Factor I, Resistance To, Breast Neoplasms

NCT01264081 2019-11-13

Lapatinib in Stage IV Melanoma With ERBB4 Mutations

Phase 2 Terminated

34 enrolled 11 charts

Dermatologic

Melanoma, Skin Neoplasms

NCT00096447 2019-07-24

Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Phase 2 Completed

31 enrolled 13 charts

Gynecologic

Endometrial Neoplasms

NCT00113373 2019-07-24

Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer

Phase 2 Completed

28 enrolled 11 charts

Gynecologic

Carcinoma, Ovarian Epithelial

NCT00826241 2019-03-22

Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma

Phase 2 Completed

58 enrolled 11 charts

CNS

Brain Neoplasms, Ependymoma, Spinal Cord Neoplasms

NCT00107003 2018-07-05

GW572016 to Treat Recurrent Malignant Brain Tumors

Phase 2 Completed

9 enrolled

CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Gliosarcoma

NCT00101036 2018-04-20

Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery

Phase 2 Completed

57 enrolled 9 charts

Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular

NCT00118157 2017-12-04

Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen

Phase 2 Completed

19 enrolled 6 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT01688609 2017-09-11

Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer

Phase 2 Completed

18 enrolled 7 charts

Breast

Breast Neoplasms

NCT00095563 2017-04-18

Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers

Phase 2 Completed

40 enrolled 9 charts

Head & Neck

Salivary Gland Neoplasms

NCT00107536 2015-04-29

Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer

Phase 2 Completed

26 enrolled 11 charts

Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular

NCT00114283 2015-04-15

Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

Phase 2 Completed

30 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT00103194 2014-09-30

Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer

Phase 2 Completed

49 enrolled 8 charts

Genitourinary

Prostatic Neoplasms

NCT00098631 2014-01-07

Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

Phase 2 Completed

88 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT00098605 2013-06-06

Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases

Phase 2 Completed

37 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms, Breast Neoplasms, Male

NCT00095667 2013-05-08

Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer

Phase 2 Completed

41 enrolled

Genitourinary

Prostatic Neoplasms

NCT00103324 2013-01-17

S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer

Phase 2 Completed

40 enrolled

Gastrointestinal

Stomach Neoplasms